Savi Albendazol 200 medicine for infection with tapeworm larvae with brain damage (1 blister x 2 tablets)

drugs: Worms.

albendazole is a carbamat benzimidazole derivative, in terms of structure related to Mebendazol. The drug has a broad -active spectrum on intestinal worms such as hookworms (Ancylostoma duodenale), mine worms (Necator Americanus), roundworm (Ascaris lumbricoides), needle worms (enterobius vericularis), eelworm (Strongyloides stercoralis), Hairworm (Trichuris Trichurail) (Capillaria Philippinensis); Trichinella Spiralis) and migrant larvae in muscle and skin; Turine tapeworms and tissue larvae (such as echinococcus granulosus, e.multilocularis and e. neurocysticercosis).

Albendazole is active in both adulthood and larval stage of intestinal worms and killing eggs of roundworms and hairworms. The main metabolic form of albendazol is Albendazol Sulfoxid still works and holds an important position of the pharmacological effect of the drug.

The mechanism of action of albendazole is similar to other benzimidazols. The drug is associated with the sub -parasite's sub -parasites, thereby inhibiting the coincidence of the sub -sub -trailers into the minor microorganisms of the cytoplasmic cells that are essential for the normal activity of the parasitic cell.

Dynamic pharmacokinetics

In humans, after drinking, Albendazol is very absorbed very poorly (5%). Most anti -helminth effects occur in the intestine. To have the effect of tissue, high and long -term doses.

Due to a very strong step of metabolism, albendazol is not seen or only seen in the form of plasma traces.

After taking a single dose of 400 mg of albendazol, the peak concentration of sulfoxid metabolites achieved in plasma is about 0.04 - 0.55 micrograms/ml after 1 to 4 hours. When taking the drug with fat foods, plasma concentrations increased to 2-4 times. There is a great difference between individuals in albendazol sulfoxid levels in plasma. It may be due to erratic absorption and due to the difference in the speed of drug metabolism.

Albendazol Sulfoxid binds to protein in plasma up to 70%. When used for long -term use in the treatment of tapeworms, the concentration of albendazol sulfoxid in tapeworm fluid can reach about 20% of plasma concentrations. Albendazol Sulfoxid through the bloody barrier and concentration in the brain - marrow is about 1/3 of the plasma concentration.

Albendazole is rapid and completely oxidized, into a metabolic substance that still has the effect of Albendazol Sulfoxid, then converted into a compound no longer acting, Albendazol Sulfon.

albendazole has a half -life from plasma for about 9 hours. Sulfoxid metabolites are eliminated through the kidneys along with sulfon metabolites and other metabolites. A negligible amount of sulfoxid metabolism is excreted through bile.

Be cautious when using

need to be very careful when taking the drug for patients in the following cases:

bone marrow inhibition

The drug can be fatal caused by decreased granulocytes or all blood cells. Albendazole can cause bone marrow inhibition, non -regenerated anemia and grain leukocytes. Monitoring blood formula at the beginning of the treatment cycle every 28 days and every 2 weeks while treatment with Savi Albendazol 200. Patients with liver disease or liver fluke infection are at higher risk of bone marrow inhibitor than others and must regularly monitor blood formulas. Stop using Savi Albendazol 200 if significantly reduced the number of blood cells.

The monster effect

albendazole may be harmful to the fetus and should not be used in pregnant women except for no other choice. Check pregnancy before prescribing women who are likely to get pregnant. Advise them to take effective contraception during the Savi Albendazol 200 treatment period and in a month after the end of the therapy. Stop the drug immediately if the patient is pregnant and evaluate the patient about the potential risk to the fetus.

The risk of neurological symptoms in patients infected with tapeworm larvae with brain damage

Patients who are treating tapeworm larvae with brain damage should be used for steroids and anticonvulsants to prevent neurological symptoms (such as shock, increased intracranial pressure and chest signs) caused by inflammatory reactions when parasites die in the brain.

Risk of retinal damage to patients infected with tapeworm larvae in the retina

Perfume disease can affect the retina. Before starting treatment for patients, it is necessary to check whether retinal damage or not. If so, should be reminded when using the drug because it is likely to damage the retina caused by the inflammatory reaction when the parasite die.

Effects in the liver

Albendazole treatment can cause increased liver enzymes from mild to moderate in 16% of patients and will return to normal after stopping treatment. There have been reports on acute liver failure for unknown causes and hepatitis.

Check the liver enzyme (transaminase) before starting each treatment cycle and at least every 2 weeks throughout the treatment process. If the liver enzyme exceeds the upper limit of the normal level, depending on the condition of the patient, it is advisable to consider stopping treatment with albendazol. When the liver enzyme returns to normal, it is necessary to consider the benefits and the risk of continuing the use of albendazol. Should check the liver enzyme regularly if used again.

Patients with an increased enzyme test results are at risk of increasing toxicity on the liver and bone marrow. Stop treatment if the liver enzyme increases significantly or decreases the number of blood cells.

Detects infection with tapeworm larvae with brain damage in patients with cyst disease

Infection with tapeworm larvae with brain damage can be detected in patients using albendazol to treat other diseases. Patients with risk factors are prone to infection with tapeworm larvae with brain damage should be assessed before starting treatment.

excipients

Due to the presence of lactose in preparations, patients with rare genetic disorders in glucose tolerance, lactase lactase deficiency or glucose-galactose absorption disorders should not be used.

The effect of the drug on the ability to drive and operate machinery

Based on the pharmacological characteristics of unwanted effects such as headache, dizziness, nausea, vomiting should have albendazol potential affecting alertness when driving or operating machinery. It should be recommended that patients when using albenda-zol should not drive or control machines.

Use drugs for women during pregnancy and lactation

Pregnancy

Do not use albendazol for pregnant women except for cases of mandatory use without any other way. Patients must not be pregnant for at least one month after using albenda-zol. If the patient is taking the drug and if he is pregnant, he/she must stop the drug immediately and must understand that the drug can cause serious danger to the fetus.

Breastfeeding period

Do not know what level of the drug in milk. Therefore, it is necessary to be very careful when using albendazol for nursing women.

Drug interaction